STOCKHOLM, SWEDEN April 14, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that it is exercising its share of the portfolio company Modus Therapeutics’ warrant program series 2025/2026 (TO2).
The exercise period in the portfolio company Modus Therapeutics’ warrant program TO2 runs between April 13–24 2026, and the subscription price amounts to SEK 0.35 per share. KDventures is exercising all of its warrants, corresponding to approximately SEK 5.1 million.
Upon full exercise of the warrant program, Modus Therapeutics, listed on Nasdaq First North Growth Market, will receive about SEK 10 million before transaction costs.
KDventures' ownership in Modus Therapeutics amounts to 56 percent directly and 2 percent indirectly via KDev Investments.